Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STANDLOW low-dose versus standard-dose antiepileptic drugs in newly diagnosed epilepsy
2018-000781-10Phase 4Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of carbamazepine, oxcarbazepine, lamotrigine, levetiracetam, topiramate and 3 more in epilepsy (2 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Treatment failure due to seizure relapse. Started Jun 2021; status: completed.
02
Drugs
carbamazepineoxcarbazepinelamotriginelevetiracetamtopiramate
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2018-000781-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000781-10.